Мalignant transformation of endometrial hyperplasia: epidemiology and prognosis

• Roya G. Huseynova
• Irina M. Ordiyants
• Anastasia A.Yamurzina
• Naira L. Sargsyan
• Sevinj Yadulla kyzy Ismailzade

Abstract

To date, endometrial cancer is in second place in terms of prevalence after tumor diseases of the breast. In the Russian Federation, the incidence of endometrial cancer over the past decade has increased from 119.9 to 175.5 cases per 100 thousand female population. In the general structure of oncological morbidity, the proportion of patients with endometrial malignant neoplasms is about 7.1%. To date, the study of the problem of endometrial hyperplastic processes and its malignant transformation is an urgent scientific and practical problem. The search for complex algorithms for effectively predicting the development of malignant neoplasms should be carried out along the path from the analysis of large population risk factors to fine molecular mechanisms for the selection of optimal individualized methods of diagnosis and treatment. The article provides an overview of domestic and foreign sources on the problem of endometrial hyperplastic processes and its malignant transformation.

Keywords:endometrial hyperplasia, endometrial cancer, risk factors

References

1. Petrova G.V. et al. The state of cancer care for the population of Russia in 2017 according to federal statistical observation. Onkologiya. Zhurnal imeni P.A. Gertsena [Oncology. Zhurnal named after P.A. Gertsen]. 2019; 8 (1): 32-40. (in Russian)

2. Arem H., Irwin M.L. Obesity and endometrial cancer survival: a systematic review. Int J Obes. 2013; 37 (5): 634-9.

3. Burke W.M., et al. Endometrial cancer: a review and current management strategies: Part II. Gynecol Oncol. 2014; 134 (2): 393-402.

4. Cramer D.W. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am. 2012; 26 (1): 1-12.

5. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68 (1): 7-30.

6. Aksel E.M. Statistics of malignant neoplasms of female reproductive organs Onkoginekologiya [Oncogynecology]. 2018; 27 (3): 64-78. (in Russian)

7. Binder P.S., Mutch D.G. Update on prognostic markers for endometrial cancer. Womens Health. 2014; 10 (3): 277-88.

8. Kiselev V. I. Hyperplastic processes of the organs of the female reproductive system: theory and practice.Moscow: Medpraktika-M, 2011: 467 p. (in Russian)

9. Singh G., Puckett Y. Endometrial Hyperplasia. StatPearls Publishing, 2020.

10. Sobczuk K., Sobczuk A. New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. Prz Menopauzalny. 2017; 16 (3): 107-11.

11. Cullen T. Cancer of the Uterus: Its Pathology, Symptomatology, Diagnosis, and Treatment, New York: Appleton-Century Company, 1900.

12. Kadirogullari P., et al. Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J Clin Diagn Res. 2015; 9 (10): QC10-4.

13. Adamyan L.V., et al. Concomitant benign tumors and hyperplastic processes of the uterus (myoma, adenomyosis, endometrial hyperplasia). Moscow: NTs akusherstva, ginekologii i perinatologii imeni akademika V.I. Kulakova, 2015: 104 p. (in Russian)

14. Chernukha G.E., et al. The structure of endometrial pathology in different age periods.Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2018; (8): 129-34. (in Russian)

15. Kulavsky V.A. et al. Etiopathogenesis of endometrial hyperplastic processes in women of reproductive age.Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2019; 14 (2): 71-80. (in Russian)

16. Chandra V., et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (1): 1-25.

17. Erdem B., et al. Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? Int J Surg. 2018; 53: 350-3.

18. Iversen M.L., Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9-14 years. Eur J Obstet Gynecol Reprod Biol. 2018; 222: 171-5.

19. Raglan O., et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019; 145 (7): 1719-30.

20. Zhang K., et al. Effects of bariatric surgery on cancer risk: evidence from meta-analysis. Obes Surg. 2020; 30 (4): 1265-72.

21. Kalliala I., et al. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ. 2017; 359: j4511.

22. Kyrgiou M., et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ Online. 2017; 356: ID j477.

23. Baburin D.V., et al. Endometrial hyperplastic processes in peri-menopausal women: clinical aspects of the problem.Arkhiv akusherstva i ginekologii imeni V.F. Snegireva [Archive of Obstetrics and Gynecology named after V.F. Snegirev]. 2017; 4 (4): 201-7. (in Russian)

24. Kolesova T.E., et al. The value of risk factors assessment in the diagnosis of endometrial cancer. In: Oncology - XXI century. Knizhniy format, 2017: 123-7. (in Russian)

25. Tsilidis K.K., et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ Online. 2015; 350: g7607.

26. Mitsuhashi A., et al. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017; 25 (5): 1495-501.

27. Raffone A., et al. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol. 2019; 35 (11): 932-7.

28. Raffone A., et al. Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res. 2020; 26 (3): 1377-84.

29. Nead K.T., et al. Evidence of a causal association between insu-linemia and endometrial cancer: a Mendelian randomization analysis. J Natl Cancer Inst. 2015; 107 (9): 178.

30. Epplein M., et al. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol. 2008; 168 (6): 563-70.

31. Wu Q.J., et al. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep. 2015; 5: 14243.

32. Fleming C.A., et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg. 2018; 105 (9): 1098-106.

33. Davies C., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381 (9869): 805-16.

34. Dmitrieva E.V. Endometrium in the treatment of breast tumor with tamoxifen in postmenopausal women: Diss. Moscow, 2016. (in Russian)

35. Aune D., et al. Anthropometric factors and endometrial cancer risk: f systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015; 26 (8): 1635-48.

36. Kaaks R., Lukanova A., Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002; 11 (12): 1531-43.

37. Viswanathan A.N., et al. Smoking and the risk of endometrial cancer: results from the nurses' health study. Int J Cancer. 2005; 114 (6): 996-1001.

38. World Cancer Research Fund International/American Institute for Cancer Research — Google Scholar [Electronic resource]. URL: https://scholar.google.com/ (date of access October 19, 2020)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)